Tuesday, 14 January 2025
by BD Banks
Moderna‘s (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down — a lot.
The coronavirus vaccine maker’s shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an “endemic” illness rather than a novel and spreading pandemic. CEO Stéphane Bancel said Moderna has cut its “cash operating cost by over 25 percent compared to 2023” and plans to make further cost cuts of $1 billion in 2025 and $500 million more in 2026, which should boost profits.
That’s the good news.
The bad news is that as Moderna heads into the new year, it foresees continued sales declines in its vaccines business. 2025 sales estimates range from only $1.5 billion to $2.5 billion, implying at least a 17% decline in sales this year and potentially a 52% crash. In this context, cutting $1 billion in costs may be the very least Moderna needs to do just to tread water on profits.
Moderna’s guidance took Wall Street by surprise, as analysts had been forecasting 2025 sales in the neighborhood of $2.9 billion. Even in the most optimistic scenario, Moderna will now miss that number by at least 14%. At the midpoint of management’s guidance, Moderna will fall 31% short of Wall Street’s goal.
In summary, Moderna’s business thrived as it helped combat the pandemic, turning the company suddenly profitable in both 2021 and 2022. Now that the pandemic is over, though — or, as Moderna says, the virus has become “endemic” — the company has a long, hard road ahead of it.
Most analysts polled by S&P Global Market Intelligence don’t see Moderna turning profitable again until 2029 at the earliest. If today’s guidance wasn’t enough to scare you away from Moderna stock, maybe those forecasts are.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of January 13, 2025
Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.